Charles Schwab
ZBIO icon

Charles Schwab’s Zenas BioPharma ZBIO Stock Holding History

Charles Schwab’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.67M Buy
302,085
+77,683
+35% +$1.54M ﹤0.01% 2281
2026
Q1 		$4.39M Buy
224,402
+11,209
+5% +$252K ﹤0.01% 2456
2025
Q4 		$7.74M Buy
213,193
+34,797
+20% +$1.14M ﹤0.01% 2254
2025
Q3 		$3.96M Buy
178,396
+56,186
+46% +$915K ﹤0.01% 2531
2025
Q2 		$1.18M Buy
122,210
+6,070
+5% +$59.1K ﹤0.01% 2847
2025
Q1 		$918K Sell
116,140
-2,520
-2% -$19.7K ﹤0.01% 2869
2024
Q4 		$972K Buy
+118,660
New +$1.85M ﹤0.01% 2924

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Charles Schwab's ZBIO Position: Q2 2026 in Review

Charles Schwab increased its Zenas BioPharma (ZBIO) stake by 35% in Q2 2026, buying an estimated $1.54M and bringing the position to 302,085 shares worth $7.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2281.

Charles Schwab first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.74M in Q4 2025. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Charles Schwab held 302,085 shares of Zenas BioPharma worth $7.67M as of Q2 2026.
  • Charles Schwab bought 77,683 Zenas BioPharma shares in Q2 2026, an estimated $1.54M.
  • Zenas BioPharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2281 holding.
  • Charles Schwab first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
  • Charles Schwab's Zenas BioPharma position peaked at $7.74M in Q4 2025.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.